On Wednesday, Canaccord Genuity maintained a Buy rating on AtriCure Inc. (NASDAQ:ATRC) and increased the price target to $53.00 from the previous $49.00. The adjustment followed AtriCure's third-quarter revenue report, which exceeded expectations. The company announced a 17.9% year-over-year increase in revenue to $115.9 million, surpassing both Canaccord Genuity and Street estimates of $111.5 million and $112.2 million, respectively.
AtriCure also revised its full-year 2024 revenue guidance upwards to a range of $459 million to $462 million, which is above Canaccord Genuity's pre-report estimate of $456.1 million. The company's adjusted EBITDA for the quarter was reported at $7.9 million, higher than the estimated $6.7 million, and was complemented by a positive cash flow of $16.3 million.
The company's performance was broadly strong across its businesses, with the exception of minimally invasive ablation/EPi-Sense, which is currently facing expected challenges due to the adoption of pulsed field ablation (PFA). However, management is confident these challenges will diminish, drawing on their experience in the European market.
Investors showed interest in AtriCure's newly announced PFA partnership, which is set to expedite the company's internal development efforts in this area. Plans to include a PFA product in AtriCure's epicardial product lineup were disclosed, with further details on the timing to be provided in the future.
The company's appendage management segment, which includes the AtriClip Flex (NASDAQ:FLEX) V, saw a revenue of $46.0 million in the third quarter. This marks a third consecutive quarter of sequential revenue acceleration in the US open franchise, where it competes with products from Medtronic (NYSE:MDT). Additionally, the recent U.S. launch of the AtriClip Flex Mini has been met with positive feedback due to its compact design.
The LeAAPS trial is progressing as expected, with 3,700 of the targeted 6,500 patients enrolled, aiming for full enrollment by mid-2025. Furthermore, pain management delivered an exceptional quarter, generating $17.9 million in revenue, a 36.3% increase year-over-year, and outperforming the consensus estimates of $15.6 million. This success was attributed to the introduction of cryoSPHERE+ and is expected to continue with the anticipated introduction of the cryoSPHERE Max probe.
Finally, Open Ablation, led by the U.S. growth of the Encompass product at 50% year-over-year, contributed $39.2 million. Although international growth for Encompass is not anticipated until 2025, the company is preparing for its launch in the fourth quarter of 2024. With the expansion of Encompass OUS for a full year and the introduction of new products like cryoSPHERE+/MAX and AtriClip Flex Mini, AtriCure is positioned for continued momentum into 2025.
In other recent news, AtriCure, Inc. has been making significant strides in its operations. The company reported robust performance in the second quarter of 2024, with total revenue reaching $116 million, a figure that represents over 15% year-over-year growth. This growth was observed across all product lines, including pain management, open ablation, and appendage management.
In addition, AtriCure has expanded its presence in Europe with the launch of the EnCompass Clamp, following regulatory approval. The company's AtriClip device also received an expanded indication in Europe, further solidifying its position in the region.
The company's financial health was underscored by a positive cash flow of more than $8 million for the quarter and a solid reserve of $114 million in cash and investments. Despite anticipating a sequential decline in Q3 revenue due to seasonality, the company expects a rebound in Q4.
InvestingPro Insights
AtriCure's recent performance and future outlook are further illuminated by data from InvestingPro. The company's market capitalization stands at $1.43 billion, reflecting investor confidence in its growth potential. This aligns with the strong revenue growth of 17.57% over the last twelve months, which supports the company's upward revision of its full-year 2024 revenue guidance.
An InvestingPro Tip highlights that AtriCure operates with a moderate level of debt, which could provide financial flexibility as it continues to invest in new product development and market expansion. This is particularly relevant given the company's ongoing investments in PFA technology and the expansion of its product lineup.
Another key metric from InvestingPro shows that AtriCure's gross profit margin is an impressive 74.84%, indicating strong pricing power and efficient cost management. This robust margin supports the company's ability to invest in research and development, crucial for maintaining its competitive edge in the medical device market.
It's worth noting that InvestingPro offers additional tips and insights for AtriCure, which could be valuable for investors looking to deepen their understanding of the company's financial position and market prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.